Jay L. Koyner, MD, is a Professor of Medicine in the Section of Nephrology at the University of Chicago where he also serves as the Medical Director of the Inpatient Dialysis Unit, Director of ICU Nephrology and the Associate Program Director of the Nephrology-Critical Care Fellowship. His clinical and research focus centers on critical care nephrology including the earlier detection of acute kidney injury (AKI) using machine-learning risk scores and novel biomarkers of tubular injury as well as improving the care delivery of patients with AKI especially those receiving continuous renal replacement therapy.
For nearly two decades Dr. Koyner has been a national and international leader in AKI research. He has contributed to the development and FDA validation of several new biomarkers as well as the standardization of the furosemide stress test, all of which can be used for more accurate prediction for the development of severe AKI. Having worked to bring these tools from research studies to clinical use his work has improved the care of patients at risk for AKI as well as those with established early AKI.
In addition to his research efforts, Dr. Koyner is an accomplished educator having created and directed the Nephrology fellowship’s Intensive Care Unit rotations. On the national level he has directed the American Society of Nephrology’s Critical Care Nephrology pre-course and edited of the Nephrology Self-Assessment Program (NephSAP) for Acute Kidney Injury and Critical Care Nephrology. More recently he has served as the primary editor of the Handbook of Critical Care Nephrology.
Dr. Koyner is actively involved in training the next generation of critical care nephrologists as well as residents, medical students and undergraduates. He has published over 100 peer reviewed articles, book chapters and consensus care documents and has served on the editorial boards of several prominent nephrology and critical care journals.
As the medical director of the inpatient acute dialysis unit, he continues to innovate and provide cutting edge care to hospitalized patients at the University of Chicago. This includes establishing a Molecular Adsorbent Recirculating System (MARS) program to improve the care of patients with combined liver-kidney injury as well as establishing protocols to assist in administrating Chimeric Antigen Receptor T-Cell (CAR-T) therapy to patients with end-stage kidney disease and dialysis requiring AKI.
The University of Chicago
Chicago. IL
- Nephrology
2006
The University of Chicago
Chicago
- Internal Medicine
2004
Stony Brook School of Medicine
Stony Brook, NY
MD - Medicine
2001
The Johns Hopkins University
Baltimore, MD
BA - Biophysics
1996
Validation of Urinary C-C Motif Chemokine Ligand 14 for Persistent Severe AKI Using Clinical Adjudication.
Validation of Urinary C-C Motif Chemokine Ligand 14 for Persistent Severe AKI Using Clinical Adjudication. Clin J Am Soc Nephrol. 2026 Sep 16.
PMID: 42747895
AKI as a systemic syndrome and its impact on other organ systems.
AKI as a systemic syndrome and its impact on other organ systems. Crit Care. 2026 Aug 22; 30(1).
PMID: 42632888
Accelerating Evidence-Based Practices in Acute Kidney Injury: A Consensus Statement from the XXXV ADQI Conference.
Accelerating Evidence-Based Practices in Acute Kidney Injury: A Consensus Statement from the XXXV ADQI Conference. Clin J Am Soc Nephrol. 2026 Jul 31.
PMID: 42537020
Early Nephrology Consultation and Acute Kidney Injury in Hospitalized Patients: A Randomized Clinical Trial.
Early Nephrology Consultation and Acute Kidney Injury in Hospitalized Patients: A Randomized Clinical Trial. JAMA Netw Open. 2026 07 01; 9(7):e2622554.
PMID: 42430171
Epidemiology of hyperkalemia among US emergency department patients without end-stage renal disease from 2016 to 2024.
Epidemiology of hyperkalemia among US emergency department patients without end-stage renal disease from 2016 to 2024. Clin Exp Emerg Med. 2026 Jun; 13(2):159-166.
PMID: 41606795
Variability in Antibiotic Dosing and Resistance Development during Continuous Renal Replacement Therapy in Critically Ill Patients.
Variability in Antibiotic Dosing and Resistance Development during Continuous Renal Replacement Therapy in Critically Ill Patients. Blood Purif. 2026; 55(3-4):197-209.
PMID: 41528937
Transforming nephrology through artificial intelligence: a state-of-the-art roadmap for clinical integration.
Transforming nephrology through artificial intelligence: a state-of-the-art roadmap for clinical integration. Clin Kidney J. 2026 Feb; 19(2):sfag004.
PMID: 41704427
Cost-Utility Analysis of Renal Replacement Therapy Modalities in the Management of Severe Acute Kidney Injury in US Critically Ill Patients.
Cost-Utility Analysis of Renal Replacement Therapy Modalities in the Management of Severe Acute Kidney Injury in US Critically Ill Patients. Clinicoecon Outcomes Res. 2025; 17:931-944.
PMID: 41426351
Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series.
Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series. Kidney Med. 2025 Dec; 7(12):101141.
PMID: 41342049
ICU digital health tools and biomarkers in renal system care.
ICU digital health tools and biomarkers in renal system care. Curr Opin Crit Care. 2025 Dec 01; 31(6):628-636.
PMID: 41198634
Mid-Career Award
American Society of Nephrology
2019